J&J Files 8-K on Multiple Debt Offerings

Ticker: JNJ · Form: 8-K · Filed: 2025-02-26T00:00:00.000Z

Sentiment: neutral

Topics: debt-offering, financing, notes

TL;DR

J&J just dropped a massive debt filing – raising billions across multiple note maturities.

AI Summary

On February 26, 2025, Johnson & Johnson filed an 8-K report detailing various debt issuances. These include $1.150 billion in notes due November 2028, $3.20 billion in notes due November 2032, $1.650 billion in notes due 2035, $3.350 billion in notes due November 2036, and $3.550 billion in notes due November 2044.

Why It Matters

This filing indicates Johnson & Johnson is raising significant capital through various debt instruments, which could impact its financial leverage and future investment strategies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of debt issuance and does not present immediate risks to the company.

Key Numbers

Key Players & Entities

FAQ

What is the total aggregate principal amount of the notes issued by Johnson & Johnson?

The total aggregate principal amount of the notes issued is $12.90 billion, comprising $1.150B (2028), $3.20B (2032), $1.650B (2035), $3.350B (2036), and $3.550B (2044).

What are the maturity dates for the notes issued?

The notes have maturity dates in November 2028, November 2032, 2035, November 2036, and November 2044.

What is the purpose of these debt issuances?

The filing does not explicitly state the purpose of these debt issuances, but they are typically for general corporate purposes, including funding operations, acquisitions, or refinancing existing debt.

When was this 8-K report filed?

This 8-K report was filed on February 26, 2025.

What is the SIC code for Johnson & Johnson?

The Standard Industrial Classification (SIC) code for Johnson & Johnson is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001193125-25-036773.txt : 20250226 0001193125-25-036773.hdr.sgml : 20250226 20250226162321 ACCESSION NUMBER: 0001193125-25-036773 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 25 CONFORMED PERIOD OF REPORT: 20250226 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25670472 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 d863514d8k.htm 8-K 8-K One Johnson & Johnson Plaza false 0000200406 0000200406 2025-02-26 2025-02-26 0000200406 us-gaap:CommonStockMember 2025-02-26 2025-02-26 0000200406 jnj:A1.150NotesDueNovember2028Member 2025-02-26 2025-02-26 0000200406 jnj:A3.20NotesDueNovember2032Member 2025-02-26 2025-02-26 0000200406 jnj:A1.650NotesDue2035Member 2025-02-26 2025-02-26 0000200406 jnj:A3.350NotesDueNovember2036Member 2025-02-26 2025-02-26 0000200406 jnj:A3.550NotesDueNovember2044Member 2025-02-26 2025-02-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2025     Johnson & Johnson (Exact name of registrant as specified in its charter)       New Jersey   1-3215   22-1024240 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey 08933 (Address of Principal Executive Offices) Registrant’s telephone number, including area code: 732 - 524-0400     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $1.00   JNJ   New York Stock Exchange 1.150% Notes Due November 2028   JNJ28   New York Stock Exchange 3.200% Notes Due June 2032   JNJ32   New York Stock Exchange 1.650% Notes Due May 2035   JNJ35   New York Stock Exchange 3.350% Notes Due June 2036   JNJ36A   New York Stock Exchange 3.550% Notes Due June 2044   JNJ44   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Ite

View on Read The Filing